Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes

Cells. 2020 Mar 13;9(3):706. doi: 10.3390/cells9030706.

Abstract

Obesity has been described as a global epidemic and is a low-grade chronic inflammatory disease that arises as a consequence of energy imbalance. Obesity increases the risk of type 2 diabetes (T2D), by mechanisms that are not entirely clarified. Elevated circulating pro-inflammatory cytokines and free fatty acids (FFA) during obesity cause insulin resistance and ß-cell dysfunction, the two main features of T2D, which are both aggravated with the progressive development of hyperglycemia. The inflammatory kinase c-jun N-terminal kinase (JNK) responds to various cellular stress signals activated by cytokines, free fatty acids and hyperglycemia, and is a key mediator in the transition between obesity and T2D. Specifically, JNK mediates both insulin resistance and ß-cell dysfunction, and is therefore a potential target for T2D therapy.

Keywords: JNK; c-Jun N-terminal kinase; glucotoxicity; inflammation; insulin resistance; lipotoxicity; obesity; type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / pathology
  • Fatty Acids, Nonesterified / metabolism
  • Glucose / metabolism
  • Humans
  • Inflammation
  • Insulin Resistance
  • Insulin Secretion
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • JNK Mitogen-Activated Protein Kinases / genetics
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Obesity / drug therapy
  • Obesity / metabolism*
  • Obesity / pathology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Fatty Acids, Nonesterified
  • Protein Kinase Inhibitors
  • JNK Mitogen-Activated Protein Kinases
  • Glucose